2017 Annual Report & Accounts

RNS Number : 8359F
ConvaTec Group PLC
26 February 2018
 

2017 Annual Report & Accounts

 

READING, UNITED KINGDOM (26 February 2018) - ConvaTec Group Plc ("ConvaTec" or the "Group"), a leading global medical products and technologies company, has today published on the Group's website its Annual Report & Accounts for the year ended 31 December 2017 (the "Annual Report").  The Annual Report is available at www.convatecgroup.com.

 

In compliance with Listing Rule 9.6.1, a copy of the Annual Report will also shortly be submitted to the National Storage Mechanism and will be available for inspection at www.morningstar.co.uk/uk/NSM.

 

The Annual Report, together with notice of the Group's Annual General Meeting to be held on 10 May 2018, will be sent to shareholders later this month, at which point a further announcement will be made.

 

Enquiries

 

Media

 

Bobby Leach, VP Group Corporate Affairs, ConvaTec                    +44 (0)7770 842 226

Alastair Elwen, Finsbury                                                             +44 (0)207 251 3801

Analysts and Investors

 

John Crosse, VP Investor Relations, ConvaTec                             +44 (0)7500 141 435

Kirsty Law, Director Investor Relations, ConvaTec                         +44 (0)7470 909 582

investorrelations@convatec.com

 

About ConvaTec


ConvaTec is a global medical products and technologies company focused on therapies for the management of chronic conditions, with leading market positions in advanced wound care, ostomy care, continence and critical care, and infusion devices. ConvaTec's products provide a range of clinical and economic benefits including infection prevention, protection of at-risk skin, improved patient outcomes and reduced total cost of care. To learn more about ConvaTec, please visit www.convatecgroup.com where a copy of this announcement can also be found.

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
ACSKMGZZKFGGRZM
UK 100

Latest directors dealings